CytoRecovery

Executive Summary

CytoRecovery, based in San Diego, is a private biotechnology company specializing in label-free cell sorting and recovery technology. Its proprietary CytoR1 Platform uses dielectrophoresis to gently separate and enrich live cells without labels or antibodies, addressing key limitations in cell therapy and regenerative medicine. The platform, along with the CytoBuffer reagent, aims to improve the purity and viability of cell populations for research and clinical applications. While the company has not disclosed funding or valuation, it has established a presence in the competitive cell therapy tools market. CytoRecovery's technology offers potential advantages in speed and gentleness compared to traditional fluorescence or magnetic sorting, but adoption hurdles include validation against established methods and scaling for manufacturing. Near-term growth depends on customer acquisition in academic and biopharma research labs, as well as potential partnerships for clinical-grade production.

Upcoming Catalysts (preview)

• Q4 2026First major commercial partnership or licensing deal for CytoR1 Platform40% success
• Q3 2026Publication of peer-reviewed data demonstrating superiority over existing cell sorting methods70% success
• Q1 2027Raising Series A or B funding to scale manufacturing and sales50% success